Type:
Educational Exhibit
Keywords:
Performed at one institution, Diagnostic or prognostic study, Retrospective, Pathology, Cancer, Imaging sequences, MR, Neuroradiology brain, Paediatric
Authors:
G. Ushanandhini1, K. Gopinathan2, P. D. J. Devimeenal2, S. prabhakaran2, V. Nadaraja2; 1chennai, Tamil Nadu/IN, 2Chennai/IN
DOI:
10.26044/ecr2020/C-14555
Background
CNS tumours constitute the second most common pediatric cancers. It is the leading cause of cancer death in children from 0 to 14 years. Majority of them involve cerebellum and brainstem.(Figure 2)
Four versions of WHO Classification of CNS tumours have been published thus far.(Figure 3)
2016 WHO classification update uses molecular parameters in addition to histology to define tumour entities, formulating a concept for how CNS tumour diagnosis should be structured in this molecular era. Including both phenotypic and genotypic parameters makes it more objective than the previous classifications. (Figure 4)
Nomenclature
2016 CNS WHO updates suggest diagnosis consisting of a histopathological type, WHO grade, followed by genetic features.
To convey the molecular, genetic and histologic data the tumour diagnosis can be reported in a systematic way with four layered schema.
Layer 1 – Final integrated diagnosis
Layer 2 – Histologic classification
Layer 3 – WHO grade
Layer 4 – Molecular information
2016 updates present major restructuring of diffuse gliomas, medulloblastomas, other embryonal tumours and addition of new entities. (Figure 5)